Cardiff Oncology, Inc.
NASDAQ:CRDFBiotechnology
+$0.03 today
- Market cap
- $65.27M
- Beta
- 1.38
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$0.65
Volume 0.86M
Average 1.05M
CRDF Sales of Investments
Cash received from selling or redeeming investments.
Cardiff Oncology, Inc.NASDAQ: CRDF
Sales of Investments · Q1 FY2026 · quarter ended Mar 2026
Sales of investments dips below year-ago levels
Q1 FY2026 sales of investments of $15.83M fell 25.4% year over year, behind the +28.1% change in trailing-twelve-month sales of investments. Sequentially, it fell 9.4% from the prior quarter. Over 3 fiscal years it compounded at -17.5% a year.
Context
- Sales of investments amounted to 12351.8% of revenue in FY2025, up 6880.2 pp from a year earlier.
- Sales of investments increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -25.4% toward the trailing-twelve-month pace of +28.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Sales of Investments history
USD · from the cash flow
- Latest · FY2025
- 73.25M USD
- Year-over-year change
- +96.0%
- 4-year CAGR
- +14.1%
| Period | Period end | Sales of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 73.25M | +96.0% |
| FY2024 | 2024-12-31 | 37.37M | -65.0% |
| FY2023 | 2023-12-31 | 106.86M | -18.0% |
| FY2022 | 2022-12-31 | 130.27M | +202.0% |
| FY2021 | 2021-12-31 | 43.14M | — |
Sales of Investments vs competitors
How CRDF compares with its peers on the latest reported figures
- Peers report in different currencies, so sales of investments is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +28.1% is the 3rd highest of 8, against a peer median of -54.2%.
- Sales of investments amounts to 12922.7% of revenue for CRDF, versus a peer median of 844.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $138.92M USD | +29.2% | +11.5% | — | |
| LTM Mar 2026 | CHF 103.25M CHF | -59.1% | -11.6% | — | |
| LTM Mar 2026 | $82M USD | -28.1% | — | — | |
| LTM Mar 2026 | $67.84M USD | +28.1% | -17.5% | 12922.7% | |
| LTM Mar 2026 | $59.86M USD | -54.2% | +48.2% | 3355.7% | |
| LTM Mar 2026 | $26.75M USD | -65.8% | +107.4% | 844.1% | |
| FY2025 | €13.51M EUR | +40.9% | +65.2% | 484.9% | |
| LTM Mar 2026 | $0 USD | -100.0% | — | — | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $0 USD | — | — | — |
| Peer median (excluding CRDF) | — | -54.2% | +48.2% | 844.1% | |
Competitors are the stored peer set for CRDF. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (28.29M) | (38.7M) | (41.44M) | (45.43M) | (45.85M) |
| Depreciation & Amortization | 451K | 236K | 398K | 404K | 904K |
| Deferred Income Tax | 1.32M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 3.23M | 4.26M | 4.51M | 4.76M | 5.69M |
| Change in Working Capital | (1.79M) | (380K) | 6.57M | 3.17M | 2.18M |
| Accounts Receivables | (215K) | (236K) | 483K | (484K) | 591K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 719K | 1.35M | 2.83M | 2.99M | 2.2M |
| Other Working Capital | (2.29M) | (1.49M) | 3.25M | 671K | (614K) |
| Other Non-Cash Items | 2.03M | 772K | (921K) | (598K) | (848K) |
| Operating Cash Flow | (23.04M) | (33.82M) | (30.89M) | (37.69M) | (37.92M) |
| Capital Expenditures | (205K) | (892K) | (582K) | (80K) | (44K) |
| Acquisitions (Net) | 205K | (114K) | 0 | 0 | 0 |
| Purchases of Investments | (174.39M) | (91.23M) | (70.08M) | (23.56M) | (71.12M) |
| Sales of Investments | 43.14M | 130.27M | 106.86M | 37.37M | 73.25M |
| Other Investing Activities | (205K) | 114K | 0 | 0 | (744K) |
| Investing Cash Flow | (131.45M) | 38.15M | 36.2M | 13.73M | 1.34M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 34.19M | 75K | 0 | 53.41M | 2.58M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | (24K) | (414K) | 0 | 0 | 0 |
| Other Financing Activities | 1.29M | 414K | 0 | 373K | 0 |
| Financing Cash Flow | 35.45M | 75K | 0 | 53.78M | 2.58M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (119.04M) | 4.4M | 5.31M | 29.82M | (34M) |
| Free Cash Flow | (23.25M) | (34.71M) | (31.47M) | (37.77M) | (37.97M) |
Cardiff Oncology, Inc.
NASDAQ:CRDF
Intrinsic Alpha fair value
Locked
Current Price
$0.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.